Teva and FTC reach settlement over ‘pay-for-delay’
20-02-2019
Teva settles Sensipar patent dispute with Amgen
04-01-2019
Teva asks FTC to reopen Actavis and Watson merger decision
24-10-2018
parbradyphoto / iStockphoto.com
The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva, Pfizer, Embeda, Federal Trade Commission, Actavis and Watson, merger, pharmaceuticals, Allergan
